机译:HCV蛋白酶抑制剂中药代动力学相互作用的临床影响Simeprevir和经常使用的伴随药物
Department of Molecular and Clinical PharmacologyUniversity of LiverpoolCrown Street Liverpool L69;
Department of Gastroenterology Hepatology and EndocrinologyHannover Medical SchoolCarl‐Neuberg‐Str;
Department of Molecular and Clinical PharmacologyUniversity of LiverpoolCrown Street Liverpool L69;
Department of Molecular and Clinical PharmacologyUniversity of LiverpoolCrown Street Liverpool L69;
Janssen Cilag Pharma GmbHEMEA Medical AffairsVorgartenstra?e 206B 1020 Vienna Austria;
Janssen PharmaceuticaTurnhoutseweg 30 2340 Beerse Belgium;
BICER Consulting &
ResearchOosterveldlaan 12 A 2610 Antwerp Belgium;
Janssen‐Cilag1 Rue Camille Desmoulins 92130 Issy‐les‐Moulineaux France;
Janssen PharmaceuticaTurnhoutseweg 30 2340 Beerse Belgium;
Janssen‐Cilag1 Rue Camille Desmoulins 92130 Issy‐les‐Moulineaux France;
Janssen Global Services LLC1125 Trenton‐Harbourton Road Titusville NJ 08560 USA;
Department of Gastroenterology Hepatology and EndocrinologyHannover Medical SchoolCarl‐Neuberg‐Str;
DDI; drug–drug interaction; HCV; hepatitis C virus; simeprevir; SMV;
机译:HCV蛋白酶抑制剂simeprevir与常用伴随药物之间药代动力学相互作用的临床影响
机译:丙型肝炎病毒(HCV)NS3基线多态性及其对HCV NS3蛋白酶抑制剂faldaprevir的临床治疗反应的影响
机译:丙型肝炎病毒(HCV)NS3基线多态性及其对HCV NS3蛋白酶抑制剂faldaprevir的临床治疗反应的影响
机译:围绕2(1H)-吡嗪酮的丙型肝炎(HCV)NS3蛋白酶抑制剂围绕R6位置的合成和SAR
机译:新型蛋白酶抑制剂Darunavir与瑞舒伐他汀之间药代动力学和药效动力学相互作用的临床前和临床研究。
机译:HCV蛋白酶抑制剂simeprevir与常用伴随药物之间药代动力学相互作用的临床影响
机译:在健康志愿者中,HCV蛋白酶抑制剂boceprevir和质子泵抑制剂奥美拉唑之间缺乏临床上重要的药物相互作用